REGENXBIO (NASDAQ:RGNX - Get Free Report) had its price objective decreased by stock analysts at HC Wainwright from $40.00 to $36.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. HC Wainwright's target price points to a potential upside of 292.16% from the company's previous close.
Several other research firms have also commented on RGNX. Morgan Stanley reiterated an "overweight" rating and issued a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, September 20th. Barclays decreased their target price on REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. Chardan Capital reissued a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a report on Wednesday. Finally, Raymond James restated an "outperform" rating and set a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, REGENXBIO currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.27.
Read Our Latest Research Report on RGNX
REGENXBIO Stock Performance
RGNX traded down $0.45 during mid-day trading on Thursday, reaching $9.18. 699,237 shares of the stock were exchanged, compared to its average volume of 623,910. The company has a 50 day moving average price of $10.37 and a two-hundred day moving average price of $12.14. The stock has a market capitalization of $454.78 million, a PE ratio of -1.83 and a beta of 1.23. REGENXBIO has a 1 year low of $8.53 and a 1 year high of $28.80.
Insiders Place Their Bets
In related news, Director Argeris N. Karabelas sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the sale, the director now owns 11,286 shares of the company's stock, valued at approximately $114,101.46. This represents a 46.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 13.13% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. FMR LLC grew its position in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,656 shares in the last quarter. nVerses Capital LLC increased its position in shares of REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 3,720 shares during the last quarter. Diversified Trust Co purchased a new stake in REGENXBIO in the second quarter valued at approximately $121,000. Finally, Arizona State Retirement System lifted its position in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company's stock valued at $137,000 after purchasing an additional 1,997 shares during the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
![Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)](https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=RGNX)
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.